Tuberculosis is the biggest bacterial killer worldwide. 1.5 million people die from TB each year due, in part, to a rise in antibiotic resistant strains, some of which are untreatable with antibiotics.
Antibiotic-resistant strains of the bacteria means that there’s an urgent need to find other ways of treating the disease. Instead of targeting the bacteria with antibiotics to combat the disease, researchers in the University of 91̽»¨â€™s Bateson Centre are focusing on how our immune systems could overcome infection.
In a recently published paper in , Dr Philip Elks and Professor Endre Kiss-Toth, both in School of Medicine and Population Health, have investigated the role of a protein family called Tribbles in the immune response to TB. Using a human tuberculosis skin test model that caused a localised immune response with collaborators in UCL, it was found that one member of the Tribbles protein family – Tribbles1 – was regulated by infection challenge. Using zebrafish larval models of tuberculosis they found that if Tribbles 1 levels were increased during infection, it protected the host against tuberculosis.
This suggests that regulating the Tribbles 1 protein could favourably influence the immune response and have a significant effect on the treatment of tuberculosis.
While Tribbles proteins have been linked to immunity for some time, their roles in bacterial infections such as tuberculosis have not previously been demonstrated. Our study uncovers an important role for Tribbles 1 in our immune defence against pathogens, opening the door for further studies investigating targeting these proteins with drugs as a new way of treating antibiotic resistant infections.
Dr Philip Elks
Senior Research Fellow, School of Medicine and Population Health